Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...

Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...

Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...

Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...

As we are a pretty opinionated bunch here at PharmaTimes, we like it when contributors are prepared to stand up and express a viewpoint. For the past few months, our expanded SmartViews section has ...

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute ...

Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in Springfield, NJ, USA, have announced the expansion of their collaborative research agreement. This partnership seeks ...